ენდოგენური პეპტიდების როლი ორგანიზმების სისტემურ თვითრეგულაციაში

Baker C., Richards L.J., Dayan C.M., Jessop D.S.Corticotropin-releasing hormone immunoreactivity in human T and B cells and macrophages: colocalization with arginine vasopressin // J. Neuroendocrinol. 2003. Vol. 15. № 11. P. 1070–1074.

Bankir L., Perucca J., Weinberger M.H. Ethnic differences in urine concentration: possible relationship to blood pressure //Clin. J. Am. Soc. Nephrol. 2007. Vol. 2. № 2. P. 304–312.

Caldwell H.K., Young W.S. III Oxytocin and vasopressin:genetics and behavioral implications // Handbook of neurochemistry and molecular neurobiology neuroactive proteins and peptides / A Lajtha, R. Lim. Berlin: Springer, 2006. P. 573–607.

Chiu T., Wu S.S., Santiskulvong C. et al. Vasopressinmediated mitogenic signaling in intestinal epithelial cells // Am. J. Physiol. Cell Physiol. 2002. Vol. 282. № 3. P. C434–450.

Dheen S.T., Tay S.S., Wong W.C. Arginine vasopressin- and oxytocin-likes immunoreactive neurons in the hypothalamic paraventricular and supraoptic nuclei of streptozotocininduced diabetic rats // Arch. Histol. Cytol. 1994. Vol. 57. № 5. P. 461–472.

Enhorning S., Wang T.J., Nilsson P.M. et al. Plasma copeptin and the risk of diabetes mellitus // Circulation. 2010. Vol. 121. № 19. P. 2102–2108.

Gallo-Payet N., Guillon G. Regulation of adrenocortical function by vasopressin // Horm. Metab. Res. 1998. Vol. 30. № 6–7. P. 360–367.

Ghosh P.M., Mikhailova M., Bedolla R., Kreisberg J.I.Arginine vasopressin stimulates mesangial cell proliferation by activating the epidermal growth factor receptor // Am. J. Physiol. Renal. Physiol. 2001. Vol. 280. № 6. P. 972–979.

Havel R.J., Goldfien A. The role of the sympathetic nervous system in the metabolism of free fatty acids // J. Lipid. Res. 1959. Vol. 1. № 1. P. 102–108.

Hiroyama M., Aoyagi T., Fujiwara Y. et al. Hypermetabolism of fat in V1a vasopressin receptor knockout mice // Mol. Endocrinol. 2007. Vol. 21. № 1. P. 247–258.

Koshimizu T.A., Nakamura K., Egashira N. et al. Vasopressin V1a and V1b receptors: from molecules to physiological systems // Physiol. Rev. 2012. Vol. 92. № 4. P. 1813–1864.

Kuro-o M. Klotho // Pflugers Arch. 2010. Vol. 459. № 2.P. 333–343.

Landry D.W., Levin H.R., Gallant E.M. et al. Vasopressin deficiency contributes to the vasodilation of septic shock // Circulation. 1997. Vol. 95. № 5. P. 1122–1125.

Luttinger D., Hernandez D.E., Nemeroff C.B., Prange A.J. Jr. Peptides and nociception // Int. Rev. Neurobiol. 1984. Vol. 25. P. 185–241.

Mavani G.P., DeVita M.V., Michelis M.F. A review of the nonpressor and nonantidiuretic actions of the hormone vasopressin // Front. Med. (Lausanne). 2015. Vol. 2.ID 19.

Ohnishi M., Razzaque M.S. Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging //FASEB J. 2010. Vol. 24. № 9. P. 3562–3571.

Park S.J., Shin J.I. Inflammation and hyponatremia: an underrecognized condition? // Korean J. Pediatr. 2013. Vol. 56. № 12. P. 519–522.

Pasquali R., Gagliardi L., Vicennati V. et al. ACTH and cortisol response to combined corticotropin releasing hormonearginine vasopressin stimulation in obese males and its relationship to body weight, fat distribution and parameters of the metabolic syndrome // Int. J. Obes. Relat. Metab. Disord. 1999. Vol. 23. № 4. P. 419–424.

Ring R.H. The central vasopressinergic system: examining the opportunities for psychiatric drug development // Curr. Pharm. Des. 2005. Vol. 11. № 2. P. 205–225.

Saleem U., Khaleghi M., Morgenthaler N.G. et al. Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome // J. Clin.Endocrinol.

Metab. 2009. Vol. 94. № 7. P. 2558–2264.